The addition of all-trans retinoic acid to pembrolizumab conferred benefit to patients with metastatic melanoma, according to results of a phase 1b/phase 2 trial published in Clinical Cancer Research.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045